Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Reducing Cannabis Use in Cannabis Use Disorder
2025-524163-21-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cannabis use disorder (CUD) comparing Semaglutide (Wegovy) with Placebo (2 arms). Primary endpoint: Reduction in total cannabis intake (grams) over the last 28 days. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on 2025-524163-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524163-21-00.